Cetera Investment Advisers
ALLO icon

Cetera Investment Advisers’s Allogene Therapeutics ALLO Stock Holding History

Cetera Investment Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,207
Closed -$14K – 4802
2025
Q4 		$14K Buy
+10,207
New +$13.5K ﹤0.01% 4599

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers's ALLO Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 10,207 shares — an estimated $14K sold.

Cetera Investment Advisers first reported a position in ALLO in Q4 2025 and held it in 1 quarter. The position peaked at $14K in Q4 2025. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 10,207 Allogene Therapeutics shares in Q1 2026, an estimated $14K.
  • Cetera Investment Advisers first reported a position in Allogene Therapeutics in Q4 2025 and held it in 1 quarter.
  • Cetera Investment Advisers's Allogene Therapeutics position peaked at $14K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.